Raxofelast, (+/-)5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acid: a new antioxidant to modulate the inflammatory response during ischemia-reperfusion injury and impaired wound healing.
Raxofelast, also named IRFI 016 or (+/-)5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acid, belongs to a family of novel molecules designed with the aim to maximize antioxidant potency of phenols related to Vitamin E (alpha-tocopherol). This review will focus on the antioxidant and radical scavenging activity of this new promising compound.
Bitto
A
A
Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy.
Minutoli
L
L
Squadrito
F
F
Polito
F
F
Altavilla
D
D
D000818:Animals; D000975:Antioxidants / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D001572:Benzofurans / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology; D015394:Molecular Structure; D015427:Reperfusion Injury / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014810:Vitamin E / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects*
D000975:Antioxidants; D001572:Benzofurans; D014810:Vitamin E; C071049:Raxofelast